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In both human and mouse it has been recently realized that natural killer (NK) cells do not emerge from the bone marrow with full
functional competence but rather acquire functions in interaction with antigen-presenting cells (APCs), primarily dendritic cells
(DCs). Here we review the mechanisms and the consequences of this NK-cell preactivation, as well as discuss new experimental
models that now allow investigating these interactions for human NK cells and their response to human pathogens in vivo. These
investigations will allow harnessing NK cells during vaccination for improved innate and adaptive immunity.
1. Introduction
Myeloid cells and natural killer (NK) cells constitute two
types of innate leucocytes that restrict infections early on
and then influence adaptive immune responses to pathogen
invasion, so that B and T cells efficiently clear invading
microorganisms. In recent years it has become apparent that
myeloid and NK cells perform their tasks not in isolation but
influence and activate each other for more efficient innate
immunity [1]. Particularly, dendritic cells (DCs), which have
long been realized to be essential sentinels to detect infections
for priming of adaptive T-cell responses [2], have recently
been shown to be crucial for efficient NK-cell responses
[3]. The diversity of DC subsets with migratory, secondary
lymphoid tissue resident, and inflammatory DCs developing
from monocytes [4] allows for a fine-tuned activation of
NK cells at different tissue sites. In addition, maturation
of these DC subsets upon encounter of different pathogen-
associated molecular patterns (PAMPs) equips them with
NK-cell stimulatory abilities adjusting to the need of stronger
or weaker NK-cell activation in the course of an immune
response [5]. These mature DCs migrate or are resident
in secondary lymphoid tissues (Figure 1), a major site of
NK-cell activation during innate immune responses [3, 6].
While in mice NK cells seem to need to home there during
immune responses [3, 7], human secondary lymphoid tissues
contain substantial amounts of NK cells [8, 9]. Thus, NK-
cell activation in secondary lymphoid tissues by mature DCs
allows for the activation of innate lymphocytes, which limit
pathogen replication prior to priming of adaptive immune
responses by the same antigen-presenting cells (APCs) at the
same sites.
Once activated, NK cells contribute to the mount-
ing immune response primarily via cytokine production
and cytotoxicity. In humans, these two functions can
be mediated by different NK-cell differentiation stages
with CD56brightCD16− NK cells preferentially producing
cytokines upon activation by APCs and terminally differ-
entiated CD56dimCD16+ NK cells being potent killers of
virus- infected and-transformed cells [10, 11]. Interestingly,
CD56brightCD16− NK cells, which primarily react to activa-
tion by mature DCs with cytokine production, with elevation
of the cytotoxic ability and with expansion, are enriched
in T-cell zones of secondary lymphoid organs [8, 9]. Thus,
human NK-cell distribution seems to be adjusted to ensure
efficient activation by DCs to rapidly mobilize the NK-cell
compartment during the initial phase of immune responses
to infections.
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Figure 1: NK-cell preactivation in secondary lymphoid organs by dendritic cells (DCs). Mature DCs preactivate NK cells in secondary
lymphoid tissues but are not killed in the process and continue to prime adaptive immune responses. They achieve this by simultaneously
transmitting IL-15-dependent activating signals via transpresentation of this cytokine in distinct domains of their synapse with DCs, while
inhibiting NK-cell lysis by engaging inhibitory receptors via MHC class I molecules occurs in other domains of the synapse center. In
addition, DC-derived IL-12 and type I IFN (IFN-α/β) increase IFN-γ production and cytotoxicity of conjugated NK cells. NK cells home to
these sites after development in the bone marrow, while mature DCs migrate there at increased frequency from peripheral tissues after their
maturation.
The present paper will summarize recent studies provid-
ing information about the molecular interactions that take
place between NK cells and myeloid antigen-presenting cells
and how these interactions can lead to completely different
outcomes for the ensuing immune responses, ranging from
immune suppression after APC editing to enhanced Th1-
polarized immune responses.
2. NK-Cell Activation by DCs—Synapses
and Cytokines
However, this rapid mobilization of cytotoxic innate effector
cells bears the risk of compromising efficient priming of
adaptive immune response due to APC killing. Indeed, NK
cells in C57BL/6 mice, which carry an activating NK-cell
receptor, Ly49H, directly engaging the viral m157 protein
of mouse cytomegalovirus (MCMV), kill MCMV-infected
DCs so efficiently that ensuing adaptive immune responses
are compromised and have difficulties controlling persistent
viral infection [12]. However, in most other instances
moderate NK-cell responses can be activated by mature DCs,
which then go on to prime protective adaptive immune
responses. This is achieved by protecting mature DCs from
NK-cell cytotoxicity during NK-cell activation, and the
immunological synapse, which mediates these interactions,
fulfills both functions. Indeed, two mechanisms have been
described by which mature DCs protect themselves from
NK-cell cytotoxicity. On the one hand, mature DCs express
serpin protease inhibitors, like protease inhibitor 9 (PI9),
that inhibit apoptosis inducing proteases, like granzyme B,
which are delivered to targets of NK-cell cytotoxicity via
perforin pores [13, 14]. On the other hand, DC maturation
upregulates surface expression of major histocompatibility
complex (MHC) class I molecules, which serve as ligands
of inhibitory receptors on NK cells of the CD94/NKG2 and
KIR families (Figure 1). Indeed, blocking of MHC class I
molecules restores mature DC killing by NK cells to levels
observed with immature DCs [15]. Furthermore, mature
DCs rapidly polarize these MHC class I molecules to their
synapses with NK cells to ensure inhibition of cytotoxicity
[16]. Therefore, mature DCs ensure in their interaction with
NK cells that they survive to allow successive priming of
adaptive immune responses.
Parallel to these inhibitory interactions, mature DCs,
however, activate resting NK cells [15, 17–19], and this inter-
action is crucial for mounting efficient NK-cell responses [3].
DC cytokine secretion or transpresented cytokines play
a major role in this NK-cell activation. While IL-12 and IL-
18 primarily stimulate cytokine production, for example of
IFN-γ, by NK cells [5, 6], type I IFN is mainly involved in
the augmentation of NK-cell cytotoxicity [20]. In addition,
IL-15, presented by IL-15Rα on mature DCs [6], can
stimulate NK-cell survival, proliferation, and differentiation
from CD56brightCD16− to CD56dimCD16+ NK cells [6, 8,
16, 21, 22]. Indeed, IL-15 is crucial for DC-mediated
activation of NK cells in mice [3]. Interestingly, these
activating interactions, especially IL-15 transpresentation to
IL-15Rβ/γc, between mature DCs and resting NK cells seem
to be mediated through distinct domains in the center of
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the immunological synapse (Figure 1) [16]. These activating
domains segregate from inhibitory domains that allow MHC
class I/KIR interactions and form rapidly within the first
minutes of mature DC interaction with NK cells. The rapid
establishment of the immunological synapse between mature
DCs and resting NK cells, which ensures NK-cell activation
and DC protection from NK-cell cytotoxicity at the same
time, seems to be important, because in vivo imaging has
revealed that DCs and NK cells might only interact with
each other in T-cell areas of secondary lymphoid tissues for
short periods of time with the majority of contacts being
around 1min [23, 24]. At these early time points, however,
the synapse between DCs and NK cells is not stabilized by
cytoskeletal components like actin. This occurs similarly to
T cells only after 20 min and might be required to exchange
all necessary signals between these two innate leucocyte
populations. Especially, IL-12 might only efficiently polarize
to the synapse at these late time points, and efficient cytokine
production by NK cells might therefore require longer
interactions with DCs [25]. This late NK-cell activation
might be further modulated by IL-18 released from DCs [26].
Thus, human NK cells, especially those resident in secondary
lymphoid tissues, might entertain longer interactions with
DCs to reach their full functional potential and might
even differentiate into CD56dimCD16+ NK cells upon this
interaction.
3. Myeloid Cell Editing by
NK Cells—Cytotoxicity and Activation
While we consider NK cells primarily as effector cells,
activated early after sensing of infections by DCs, it is
worthwhile to consider the flip side of their interaction with
DCs, namely, DC maturation by activated NK cells as well as
NK-cell regulation of other myeloid cells. In vitro activated
human NK cells can induce phenotypic maturation of DCs
via their secretion of IFN-γ and TNF-α, and these changes
are cell-contact dependent [18, 19, 27]. Monocytes have been
shown to secrete more TNF-α in the presence of activated
NK cells in a process that also was shown to require cell-
to-cell contact [28], and polymorphonuclear cells increase
their phagocytic activity and are more resistant to apoptosis
when conditioned with supernatant from cytokine-activated
NK cells [29]. Even the differentiation of CD14+ monocytes
into DCs with typical functional attributes was reported
to be induced by NK cells and was mediated by GM-CSF
production and CD154 expression by the CD56bright NK-cell
subset [30]. This shaping of the dendritic cell fate extends
to the killing of immature DCs by activated autologous NK
cells in certain in vitro settings with involvement of CD40-
CD40L interactions and the activating NK-cell receptors
(NCRs) NKp30, NKp46, and DNAM-1, whereas increased
expression of MHC class I molecules on matured DCs
protects them from NK-cell-mediated cytotoxicity [15, 19,
31–35]. Degranulation of NK cells, a surrogate for cytotoxic
activity, can be observed against human cytomegalovirus-
infected DCs, with dominant contributions of NKp46 and
DNAM-1 and exerted mainly by CD94/NKG2A+ NK cells
[36], as also reported for the cytotoxicity towards immature
DCs [34]. Human dendritic cells infected with influenza
virus increase cytotoxicity of NK cells towards autologous
immature DCs but are themselves spared from NK-cell-
mediated cytolysis, possibly due to upregulation of MHC
class I molecules [37]. As for mature DCs, upregulation of
MHC class I molecules after treatment with LPS protects
human microglial cells—resident macrophages of the central
nervous system—from NK-cell cytotoxicity [38]. Nonacti-
vated microglial cells on the other hand are efficiently killed
by activated NK cells mediated in part by the activating NCRs
NKp46 and DNAM-1 [38]. Conversely to DCs and microglia,
high-dose LPS-activated human macrophages are prone to
cytolysis mediated by autologous NK cells compared to less
activated macrophages [39], and this is also influenced by
the polarization status of macrophages [40] as well as the
pathway of macrophage activation [41]. This NK-cell cyto-
toxicity against activated macrophages was reported to be
partly dependent on IL-10-induced upregulation of NKG2D
ligands [42]. Thus, NK cells can edit myeloid antigen-
presenting cells via different mechanisms, and different
myeloid cells are differently affected. While low numbers of
activated NK cells mature DCs via cytokine secretion, high
numbers kill immature DCs, resting microglia, and activated
macrophages.
These in vitro defined interactions probably form the
basis for the modulation of adaptive immune responses
in vivo. Indeed, in the draining lymph nodes of mice,
recruitment of NK cells and NK-cell-secreted IFN-γ seem to
be essential for the establishment of Th1 responses [7]. This
NK-cell-assisted Th1 polarization renders immune responses
more efficient in the clearance of Leishmania infection [43,
44]. Furthermore, depletion of NK cells leads to altered
phenotype and numbers of DCs in lymph nodes [45, 46],
and this can lead to changes in the capacity to prime T-cell
responses [12]. Interestingly, in the early phase of mouse
cytomegalovirus infection—a mouse model for persistent
viral infections—, infected DCs are killed by activated NK
cells, and this culling of antigen-presenting cells diminished
both antiviral CD8+ and CD4+ T-cell responses which led
to an inability to clear the virus in the long run [12].
Likewise, NK-cell-mediated elimination of DCs in lymph
nodes of transplantation models inhibited alloreactive T-cell
priming [46, 47]. Furthermore, targeting of microglia by NK
cells reduced disease severity in experimental autoimmune
encephalomyelitis models [48, 49] via suppression of detri-
mental Th17 responses [49]. While, therefore, abundant acti-
vated NK cells can edit APCs to inhibit immune responses,
lower amounts of activated NK cells can mature APCs and
thereby use NK-cell recognition of cells, altered by transfor-
mation or infection, to initiate adaptive immune responses
even upstream of professional APCs like DCs. Along these
lines, NK cells, activated in vivo by tumor cell lines with
low levels of inhibitory MHC class I molecules, initiated
DC-mediated priming of protective T cells and adaptive
memory generation [50]. In a similar setting, antigen-
expressing NK-cell targets induced specific cellular as well
as humoral adaptive immune responses, possibly involving
increased uptake and antigen presentation by myeloid APCs
like DCs [51]. Thus, NK cells can influence adaptive immune
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Table 1: Distribution and frequencies of NK cells, NK-cell subsets, and myeloid cells in mice with reconstituted human immune system
components. Only data from two mouse model systems of human immune system reconstitution are shown. Frequency of NK-cell subsets
relates to total NK cells. In vivo administration of human cytokines is reported to lead to up to tenfold increases in targeted cell compartments
[22, 52]. ∗Chijioke et al., unpublished.
huNSG huRag2−/−γ−/−c
NK cells (CD3−NKp46+ or CD3−CD56+)
Bone marrow: 0.5–1.5% [52, 54]
Blood: 1–3% [52, 54]
Spleen: 1–3% [52, 54]
Thymus: not reported
Lung: 2–5% [52, 54]
Liver: 3–4.5% [52, 54]
Bone marrow: <0.2% [22]
Blood: <0.5% [22]
Spleen: <0.2% [22]
Thymus: <1% [22]
Lung: not reported
Liver: <0.4% [22]
CD56brightCD16− NK cells
Bone marrow: >30% [∗]
Blood: 25% [∗]
Spleen: 5–10% [54, ∗]
Thymus: not reported
Liver: 5% [∗]
Bone marrow: 10% [22]
Blood: not reported
Spleen: 40% [22]
Thymus: 30% [22]
Liver: not reported
CD56dimCD16+ NK cells
Bone marrow: <15% [∗]
Blood: 20% [∗]
Spleen: 30–40% [54, ∗]
Thymus: not reported
Liver: 30% [∗]
Bone marrow: 90% [22]
Blood: not reported
Spleen: 60% [22]
Thymus: 70% [22]
Liver: not reported
CD56− NK cells
Bone marrow: <10% [∗]
Blood: 30% [∗]
Spleen: 30–40% [54, ∗]
Thymus: not reported
Liver: 40–50% [∗]
Bone marrow: % not reported [22]
Blood: not reported
Spleen: % not reported [22]
Thymus: % not reported [22]
Liver: not reported
CD123+HLA-DR+ plasmacytoid DCs
Bone marrow: not reported
Spleen: 1–2% [54]
Bone marrow: 1.5–3% [22, 55]
Spleen: <0.5% [55]
CD11c+HLA-DR+ myeloid DCs
Bone marrow: 1–3% [56]
Blood: not reported
Spleen: 1–3% [54, 56]
Bone marrow: 1–3% [22, 55]
Blood: 5% [57]
Spleen: <2% [55]
CD141+HLR-DR+ myeloid DCs Spleen: <0,1% [58] Not reported
CD33+ myeloid cells
Bone marrow: 5–15% [56]
Blood: 5–10% [56]
Spleen: 5–10% [56]
Bone marrow: 20% [57]
Blood: not reported
Spleen: not reported
CD14+ monocytes/macrophages
Bone marrow: 6–10% [52, 59]
Blood: 2–5% [52, 60]
Spleen: 1–3% [52, 59]
Lung: 10–20% [52]
Liver: 5–10% [52]
Bone marrow: 2% [57]
Blood: 15% [57]
Spleen: not reported
Lung: not reported
Liver: not reported
CD66+ granulocytes Not reported
Bone marrow: 10% [57]
Blood: 5% [57]
CD15+ neutrophils
Bone marrow: 4% [59]
Spleen: 1% [59]
Not reported
∗
Chijioke et al., unpublished.
responses by at least three mechanisms. They can provide
a favorable cytokine milieu for Th1 priming by DCs, they
can kill subsets of APCs to edit or even inhibit immune
responses, and, finally, they have the capacity to even initiate
immune activation after stimulation by somatic cells.
4. NK-Cell Preactivation
and Distribution In Vivo
The in vitro studies described in the previous paragraph
examining the interplay between human NK cells and
myeloid cells mostly utilized activated NK cells, mainly acti-
vated with cytokines (in most cases IL-2), while nonactivated
or resting NK cells had lesser or no regulatory function
on the interacting myeloid cells. Equally, in mouse antiviral
immune responses in vivo, only activated NK cells, by virtue
of binding of the activating NK-cell receptor Ly49H with the
virus-encoded protein m157 on infected cells, were able to
alter antiviral T-cell responses through the killing of DCs
but not NK cells lacking the Ly49H receptor [12]. Studies
trying to assess the in vivo function of human NK cells using
mice with reconstituted human immune system components
found that these demonstrated dampened effector functions,
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however, increased to full functional competence of the NK-
cell compartment after preactivation with IL-15 or poly(I:C)
ex vivo [22, 52–54]. IL-15 was able to directly preactivate
NK cells, while poly(I:C) required splenic bystander cells to
do so, suggesting that TLR3, although expressed by human
NK cells, is not able to fully activate human NK cells in
vivo [54]. Preactivation of human NK cells also enhanced
clearing of transferred MHC class I-deficient tumor cells
in vivo [52, 54]. In addition to preactivation, IL-15, and
especially complexes of IL-15 with IL-15Rα, were able to
induce terminal differentiation of human NK cells and
significantly expanded these innate lymphocytes in vivo by
promoting the development of CD56dimCD16+ cells from
their CD56brightCD16− precursors [22, 52]. Thus, similar
to mice [3], human NK cells require preactivation by IL-
15 to reach their functional capacity in vivo. However, it is
likely that this cytokine is not produced in sufficient amounts
by the human hematopoietic cell lineages reconstituting in
these in vivo models and therefore hinders reconstitution of
similar frequencies of terminally differentiated NK cells as
seen in humans.
With respect to the production of IL-15, human myeloid
reconstitution and the location of human IL-15 producing
cells might be crucial. In this respect, terminal differentiation
of human NK cells was suggested to take place in secondary
lymphoid organs [61], and it should be important how
well these tissues are reconstituted with human myeloid
cells, especially macrophages and DCs. An overview of
human myeloid and probably myeloid cell-dependent NK-
cell reconstitution in different organs of mice with recon-
stituted human immune system components is given in
Table 1. While human myeloid cell reconstitution can be
observed in peripheral blood and spleen, reaching nearly
similar frequencies of human DCs and around one-third of
the frequency of human monocytes/macrophages compared
to the splenic and peripheral blood populations of these
cells in humans, secondary lymphoid organogenesis is
compromised in these mice, because of the deficiency in
γc-chain expression [57, 58, 60]. Often only the mesenteric
lymph node can be macroscopically observed in these mice.
Thus, enhanced myeloid reconstitution and measures to
promote secondary lymphoid tissue development in these
mice could also increase total NK-cell numbers as well as
their terminal differentiation. Additional modifications of
mice with reconstituted human immune system components
along these lines could allow the more faithful modeling of
innate immune responses in these in vivo systems of the
human immune system.
5. Conclusions
Innate lymphocyte activation by DCs has now become an
integral function of these APCs in addition to the originally
recognized priming of adaptive immunity by these cells
[1]. Especially NK cells, which are efficient innate effector
cells against tumors and virus-infected cells, are attractive
targets of this activation and desirable to be harnessed during
vaccination. As discussed above, such recruitment of NK-cell
effector functions during immunization would both directly
target infected and transformed cells, as well as influence
the adaptive immune response to vaccine antigens and to
antigenic spreading after NK-cell-mediated killing.
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